ArticleNeurocritical care2026
Neurostimulant Use and Cognitive Outcomes in Patients with Acute, Severe Traumatic Brain Injury.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe sought to examine the use of neurostimulants (NS) in the acute setting among patients with severe traumatic brain injury (TBI) and assess their impact on cognitive outcomes.
methodsWe performed a retrospective analysis of prospectively collected data from patients aged ≥ 18 years with a severe (Glasgow Coma Scale score ≤ 8), blunt TBI at eight US trauma centers from 2020 to 2023. Patients were grouped according to whether they received NS. Our primary outcome was cognitive disability at 28 days or discharge (whichever occurred first), measured by the Disability Rating Scale (DRS). A DRS score < 12 was considered a favorable outcome.
resultsThe cohort comprised 405 patients: 29.9% (n = 121) received NS and 70.1% (n = 284) did not. The most common NS was amantadine (97.5%, n = 118). The median time to NS initiation was 8.0 days (5.0-13.5), and the median treatment duration was 12.0 days (5.5-17.0). NS patients had worse injury severity scores (29 vs. 26, p = 0.02), had more neurosurgical interventions (64.4% vs. 33.2%, p < 0.0001), and were less likely to have a favorable outcome (30.8% vs. 67.1%, p < 0.0001). In a subgroup analysis of only NS patients, individuals receiving NS within 7 days of admission were three times as likely to have a favorable outcome compared to those receiving NS > 7 days after admission (odds ratio 3.01, 95% confidence interval 1.11-8.18, p = 0.03).
conclusionsNearly a third of patients with severe TBI received NS. Patients receiving NS were more injured and had worse disability at discharge compared to non-NS patients. However, among patients who received NS, treatment within 7 days was associated with an increased odds of a favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.